Traders should monitor upcoming top-line data from the Phase 3 OPERA-01 trial in fall 2026, which will be a key catalyst. While preclinical synergy is encouraging, the lack of clinical data for the OP-3136 combination means near-term upside is limited. Positive data could enhance partnership potential or valuation re-rating.
OLMA drugs
OLMA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 20 $16.58entry
- T+1 · 7mo ago +0.30%α +0.95% · $16.63
- T+5 · 7mo ago −7.78%α −8.69% · $15.29
- T+20 · 6mo ago −22.20%α −26.40% · $12.90
- T+60 · 4mo ago −28.71%α −35.49% · $11.82
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Olema Oncology released preclinical data showing palazestrant fully recruits the NCoR1 corepressor for complete estrogen receptor antagonism, and demonstrates synergistic anti-tumor activity when combined with OP-3136 in ER+/HER2- breast cancer models. The data support ongoing Phase 3 trials of palazestrant and the development of OP-3136 in combination therapy, though no clinical efficacy results were reported.
Key Facts
- Preclinical data show palazestrant recruits NCoR1, enabling complete antagonism of estrogen receptor signaling in ER+/HER2- breast cancer models.
- Combination of palazestrant and OP-3136 shows synergistic anti-tumor activity by suppressing cell-cycle and ER-driven oncogenic pathways.
- Palazestrant is in two ongoing Phase 3 trials (OPERA-01 and OPERA-02); top-line data from OPERA-01 expected in fall 2026.
- OP-3136, a KAT6 inhibitor, is in a Phase 1 trial with patient enrollment ongoing.
- Data were presented at AACR 2026, but remain preclinical, no human efficacy or safety results from combinations were disclosed.
Financial Impact
No direct financial impact disclosed; potential long-term value in combination therapy development and differentiation of palazestrant.
Risk Factors
- Preclinical results may not translate to clinical efficacy in humans.
- Delays or negative outcomes in Phase 3 trials (OPERA-01/02) could significantly impact valuation.
- Competitive landscape includes approved SERDs and next-gen endocrine therapies with clinical validation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276477 |
Track record
20 reports on OLMA
1 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +38.44% at T+60 after the Aug 9, 2026 report. 1 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.29 Now $7.36 +0.96% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $7.56 Now $7.36 −2.65% settles Feb 11
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $7.27 Now $7.36 +1.24% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $7.33 Now $7.36 +0.41% settles Feb 4
- Oct 16, 20264w ago SC 13D/A Neutral 2/10 Entry $7.11 Now $7.36 +3.52% settles Jan 14
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $6.58 Now $7.36 +11.85% settles Jan 13
- Oct 2, 20266w ago Press Release Neutral 2/10 Entry $8.25 Now $7.36 −10.79% settles Dec 30
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $10.43 to $7.54 Now $7.36 −29.43% ▼ −27.71% −27.22% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bearish 6/10 Entry $11.94 to $7.35 Now $7.36 +38.36% ▲ +38.44% +36.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers